Search Results 741-750 of 16332 for monoclonal antibody

1. Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

   ... monoclonal antibody and an immunomodulatory drug. * Must be naïve to treatment with ABBV-383. Exclusion Criteria: - Received B-cell maturation antigen (BCMA) ...

2. Daratumumab in Primary Antiphospholipid Syndrome (DARE-APS) - Mayo Clinic

   Any prior treatment with CD38 targeting monoclonal antibodies, including daratumumab or isatuximab-irfc;; Administration of the Janssen COVID-19 vaccine ...

3. Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia - Mayo Clinic

   Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a ... monoclonal antibody with the exception of blinatumomab; patients must have ...

4. Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease - Mayo Clinic

   This observational study will collect blood samples to measure sustained antibody concentrations to evaluate seroprevalence and study immunity at 6 and 12 ...

5. Dose-Escalation Study of cevostamab (BFCR4350A) in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) - Mayo Clinic

   History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins);; Patients with known ...

6. Testing the Addition of an Anti-cancer Drug, ASTX727, to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

   Patients who have received prior PD-1/PD-L1 monoclonal antibodies in any disease setting are eligible. ... antibody agent, ASTX727 is a hypomethylating ...

7. Safety Study of SEA-CD40 in Cancer Patients - Mayo Clinic

   Other monoclonal antibodies, antibody-drug conjugates, or radioimmunoconjugates: 4 weeks (2 weeks with documented disease progression);; T-cell or other cell ...

8. Mayo Clinic researchers study new class of drugs to treat multiple myeloma

   PHOENIX — Mayo Clinic researchers are studying a new class of immunotherapy drugs called "bispecific antibodies" that have demonstrated potent tumor-killing ...

9. Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer - Mayo Clinic

   Monoclonal antibodies;; Anti-HER2 or other "targeted" (e.g., mTOR) therapy. *Note: Any adverse events derived from these therapies must be ≤ Grade 2 prior ...

10. Cholangiocarcinoma Clinical Trials - Mayo Clinic Research

    Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Cobimetinib may stop the growth of tumor ...